{"id":21941,"date":"2014-11-22T21:16:45","date_gmt":"2014-11-22T20:16:45","guid":{"rendered":"http:\/\/www.w-t-w.org\/en\/?p=21941"},"modified":"2014-11-22T21:16:45","modified_gmt":"2014-11-22T20:16:45","slug":"drug-companies-return-to-core-business","status":"publish","type":"post","link":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/","title":{"rendered":"Drug Companies Return to Core Business?"},"content":{"rendered":"<p>An interesting deal between GlaxoSmithKline and Noartis involved a drug swap.\u00a0 GSK got drugs related to vaccines and Novartis got cancer drugs. Both companies got drugs they were best at selling and promoting.<\/p>\n<p>For a while, drug companies have been boltstering their roster of strengths by the acquistion of small companies that have successfully developed a drug in their field of specialty.\u00a0 Merck is to buy Idenix, a biotehnology firm.\u00a0 More than 70% of the productts of the best performing drug companies are not deeloped in house.<\/p>\n<p>The drug business now models itself on the motion picture business.\u00a0 You invest when the product appears ready to go.\u00a0 Will drug companies now meet with startups and discuss their own needs and help the start up deliver them?\u00a0 Marketing and distriution.\u00a0 This is Hollywood&#8217;s sucessful model.<\/p>\n<p style=\"text-align: center\"><a href=\"http:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/growth-by-acquisition\/\" target=\"_blank\" rel=\"attachment wp-att-21942\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-21942\" src=\"http:\/\/www.w-t-w.org\/en\/wp-content\/uploads\/2014\/11\/Growth-by-Acquisition.jpg\" alt=\"Growth by Acquisition?\" width=\"402\" height=\"279\" srcset=\"https:\/\/www.w-t-w.org\/en\/wp-content\/uploads\/2014\/11\/Growth-by-Acquisition.jpg 402w, https:\/\/www.w-t-w.org\/en\/wp-content\/uploads\/2014\/11\/Growth-by-Acquisition-300x208.jpg 300w\" sizes=\"auto, (max-width: 402px) 100vw, 402px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>An interesting deal between GlaxoSmithKline and Noartis involved a drug swap.\u00a0 GSK got drugs related to vaccines and Novartis got cancer drugs. Both companies got drugs they were best at selling and promoting. For a while, drug companies have been &hellip; <a href=\"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":22,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[23,13],"tags":[],"class_list":["post-21941","post","type-post","status-publish","format-standard","hentry","category-entrepreneurs","category-finance"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.10 - aioseo.com -->\n\t<meta name=\"description\" content=\"An interesting deal between GlaxoSmithKline and Noartis involved a drug swap. GSK got drugs related to vaccines and Novartis got cancer drugs. Both companies got drugs they were best at selling and promoting.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Adela Rogers\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.10\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"W-T-W.org - Women and Finance\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Drug Companies Return to Core Business? - W-T-W.org\" \/>\n\t\t<meta property=\"og:description\" content=\"An interesting deal between GlaxoSmithKline and Noartis involved a drug swap. GSK got drugs related to vaccines and Novartis got cancer drugs. Both companies got drugs they were best at selling and promoting.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2014-11-22T20:16:45+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2014-11-22T20:16:45+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Drug Companies Return to Core Business? - W-T-W.org\" \/>\n\t\t<meta name=\"twitter:description\" content=\"An interesting deal between GlaxoSmithKline and Noartis involved a drug swap. GSK got drugs related to vaccines and Novartis got cancer drugs. Both companies got drugs they were best at selling and promoting.\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/drug-companies-return-to-core-business\\\/#blogposting\",\"name\":\"Drug Companies Return to Core Business? - W-T-W.org\",\"headline\":\"Drug Companies Return to Core Business?\",\"author\":{\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/author\\\/adelarogers\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/wp-content\\\/uploads\\\/2014\\\/11\\\/Growth-by-Acquisition.jpg\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/drug-companies-return-to-core-business\\\/#articleImage\",\"width\":402,\"height\":279},\"datePublished\":\"2014-11-22T21:16:45+01:00\",\"dateModified\":\"2014-11-22T21:16:45+01:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/drug-companies-return-to-core-business\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/drug-companies-return-to-core-business\\\/#webpage\"},\"articleSection\":\"Entrepreneurs, Finance\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/drug-companies-return-to-core-business\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.w-t-w.org\\\/en\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/home\\\/news-blog\\\/#listItem\",\"name\":\"News Blog\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/home\\\/news-blog\\\/#listItem\",\"position\":2,\"name\":\"News Blog\",\"item\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/home\\\/news-blog\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/home\\\/news-blog\\\/finance\\\/#listItem\",\"name\":\"Finance\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/home\\\/news-blog\\\/finance\\\/#listItem\",\"position\":3,\"name\":\"Finance\",\"item\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/home\\\/news-blog\\\/finance\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/drug-companies-return-to-core-business\\\/#listItem\",\"name\":\"Drug Companies Return to Core Business?\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/home\\\/news-blog\\\/#listItem\",\"name\":\"News Blog\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/drug-companies-return-to-core-business\\\/#listItem\",\"position\":4,\"name\":\"Drug Companies Return to Core Business?\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/home\\\/news-blog\\\/finance\\\/#listItem\",\"name\":\"Finance\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/#organization\",\"name\":\"W-T-W.org\",\"description\":\"Women and Finance\",\"url\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/author\\\/adelarogers\\\/#author\",\"url\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/author\\\/adelarogers\\\/\",\"name\":\"Adela Rogers\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/drug-companies-return-to-core-business\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2ed2258ebc444ebd985f92509fea4f9954b5cba01bcaab47af90b5ea2fc8fc75?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Adela Rogers\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/drug-companies-return-to-core-business\\\/#webpage\",\"url\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/drug-companies-return-to-core-business\\\/\",\"name\":\"Drug Companies Return to Core Business? - W-T-W.org\",\"description\":\"An interesting deal between GlaxoSmithKline and Noartis involved a drug swap. GSK got drugs related to vaccines and Novartis got cancer drugs. Both companies got drugs they were best at selling and promoting.\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/drug-companies-return-to-core-business\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/author\\\/adelarogers\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/author\\\/adelarogers\\\/#author\"},\"datePublished\":\"2014-11-22T21:16:45+01:00\",\"dateModified\":\"2014-11-22T21:16:45+01:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/\",\"name\":\"W-T-W.org\",\"description\":\"Women and Finance\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.w-t-w.org\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Drug Companies Return to Core Business? - W-T-W.org","description":"An interesting deal between GlaxoSmithKline and Noartis involved a drug swap. GSK got drugs related to vaccines and Novartis got cancer drugs. Both companies got drugs they were best at selling and promoting.","canonical_url":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/#blogposting","name":"Drug Companies Return to Core Business? - W-T-W.org","headline":"Drug Companies Return to Core Business?","author":{"@id":"https:\/\/www.w-t-w.org\/en\/author\/adelarogers\/#author"},"publisher":{"@id":"https:\/\/www.w-t-w.org\/en\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/www.w-t-w.org\/en\/wp-content\/uploads\/2014\/11\/Growth-by-Acquisition.jpg","@id":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/#articleImage","width":402,"height":279},"datePublished":"2014-11-22T21:16:45+01:00","dateModified":"2014-11-22T21:16:45+01:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/#webpage"},"isPartOf":{"@id":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/#webpage"},"articleSection":"Entrepreneurs, Finance"},{"@type":"BreadcrumbList","@id":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.w-t-w.org\/en#listItem","position":1,"name":"Home","item":"https:\/\/www.w-t-w.org\/en","nextItem":{"@type":"ListItem","@id":"https:\/\/www.w-t-w.org\/en\/home\/news-blog\/#listItem","name":"News Blog"}},{"@type":"ListItem","@id":"https:\/\/www.w-t-w.org\/en\/home\/news-blog\/#listItem","position":2,"name":"News Blog","item":"https:\/\/www.w-t-w.org\/en\/home\/news-blog\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.w-t-w.org\/en\/home\/news-blog\/finance\/#listItem","name":"Finance"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.w-t-w.org\/en#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.w-t-w.org\/en\/home\/news-blog\/finance\/#listItem","position":3,"name":"Finance","item":"https:\/\/www.w-t-w.org\/en\/home\/news-blog\/finance\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/#listItem","name":"Drug Companies Return to Core Business?"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.w-t-w.org\/en\/home\/news-blog\/#listItem","name":"News Blog"}},{"@type":"ListItem","@id":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/#listItem","position":4,"name":"Drug Companies Return to Core Business?","previousItem":{"@type":"ListItem","@id":"https:\/\/www.w-t-w.org\/en\/home\/news-blog\/finance\/#listItem","name":"Finance"}}]},{"@type":"Organization","@id":"https:\/\/www.w-t-w.org\/en\/#organization","name":"W-T-W.org","description":"Women and Finance","url":"https:\/\/www.w-t-w.org\/en\/"},{"@type":"Person","@id":"https:\/\/www.w-t-w.org\/en\/author\/adelarogers\/#author","url":"https:\/\/www.w-t-w.org\/en\/author\/adelarogers\/","name":"Adela Rogers","image":{"@type":"ImageObject","@id":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/2ed2258ebc444ebd985f92509fea4f9954b5cba01bcaab47af90b5ea2fc8fc75?s=96&d=mm&r=g","width":96,"height":96,"caption":"Adela Rogers"}},{"@type":"WebPage","@id":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/#webpage","url":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/","name":"Drug Companies Return to Core Business? - W-T-W.org","description":"An interesting deal between GlaxoSmithKline and Noartis involved a drug swap. GSK got drugs related to vaccines and Novartis got cancer drugs. Both companies got drugs they were best at selling and promoting.","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/www.w-t-w.org\/en\/#website"},"breadcrumb":{"@id":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/#breadcrumblist"},"author":{"@id":"https:\/\/www.w-t-w.org\/en\/author\/adelarogers\/#author"},"creator":{"@id":"https:\/\/www.w-t-w.org\/en\/author\/adelarogers\/#author"},"datePublished":"2014-11-22T21:16:45+01:00","dateModified":"2014-11-22T21:16:45+01:00"},{"@type":"WebSite","@id":"https:\/\/www.w-t-w.org\/en\/#website","url":"https:\/\/www.w-t-w.org\/en\/","name":"W-T-W.org","description":"Women and Finance","inLanguage":"en-US","publisher":{"@id":"https:\/\/www.w-t-w.org\/en\/#organization"}}]},"og:locale":"en_US","og:site_name":"W-T-W.org - Women and Finance","og:type":"article","og:title":"Drug Companies Return to Core Business? - W-T-W.org","og:description":"An interesting deal between GlaxoSmithKline and Noartis involved a drug swap. GSK got drugs related to vaccines and Novartis got cancer drugs. Both companies got drugs they were best at selling and promoting.","og:url":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/","article:published_time":"2014-11-22T20:16:45+00:00","article:modified_time":"2014-11-22T20:16:45+00:00","twitter:card":"summary_large_image","twitter:title":"Drug Companies Return to Core Business? - W-T-W.org","twitter:description":"An interesting deal between GlaxoSmithKline and Noartis involved a drug swap. GSK got drugs related to vaccines and Novartis got cancer drugs. Both companies got drugs they were best at selling and promoting."},"aioseo_meta_data":{"post_id":"21941","title":"","description":"An interesting deal between GlaxoSmithKline and Noartis involved a drug swap.  GSK got drugs related to vaccines and Novartis got cancer drugs. Both companies got drugs they were best at selling and promoting.","keywords":[{"label":"Swap","value":"Swap"},{"label":"buy","value":"buy"},{"label":"invent","value":"invent"},{"label":"Big Pharma","value":"Big Pharma"},{"label":"GSK","value":"GSK"},{"label":"Merck","value":"Merck"},{"label":"","value":""}],"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2024-10-06 06:22:47","updated":"2025-07-13 23:33:46","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.w-t-w.org\/en\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.w-t-w.org\/en\/home\/news-blog\/\" title=\"News Blog\">News Blog<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.w-t-w.org\/en\/home\/news-blog\/finance\/\" title=\"Finance\">Finance<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tDrug Companies Return to Core Business?\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.w-t-w.org\/en"},{"label":"News Blog","link":"https:\/\/www.w-t-w.org\/en\/home\/news-blog\/"},{"label":"Finance","link":"https:\/\/www.w-t-w.org\/en\/home\/news-blog\/finance\/"},{"label":"Drug Companies Return to Core Business?","link":"https:\/\/www.w-t-w.org\/en\/drug-companies-return-to-core-business\/"}],"_links":{"self":[{"href":"https:\/\/www.w-t-w.org\/en\/wp-json\/wp\/v2\/posts\/21941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.w-t-w.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.w-t-w.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.w-t-w.org\/en\/wp-json\/wp\/v2\/users\/22"}],"replies":[{"embeddable":true,"href":"https:\/\/www.w-t-w.org\/en\/wp-json\/wp\/v2\/comments?post=21941"}],"version-history":[{"count":2,"href":"https:\/\/www.w-t-w.org\/en\/wp-json\/wp\/v2\/posts\/21941\/revisions"}],"predecessor-version":[{"id":21944,"href":"https:\/\/www.w-t-w.org\/en\/wp-json\/wp\/v2\/posts\/21941\/revisions\/21944"}],"wp:attachment":[{"href":"https:\/\/www.w-t-w.org\/en\/wp-json\/wp\/v2\/media?parent=21941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.w-t-w.org\/en\/wp-json\/wp\/v2\/categories?post=21941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.w-t-w.org\/en\/wp-json\/wp\/v2\/tags?post=21941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}